<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02490020</url>
  </required_header>
  <id_info>
    <org_study_id>zssy20150624</org_study_id>
    <nct_id>NCT02490020</nct_id>
  </id_info>
  <brief_title>A Perspective Multicenter Controlled Study On Application Of Mesenchymal Stem Cell(MSC) To Prevent Rejection After Renal Transplantation By Donation After Cardiac Death</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qipeng Sun</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although donation after cardiac death(DCD) is the major source of renal transplantation in
      China, high incidence rate of rejection and delayed graft function(DGF) is existing due to
      the prolonged ischemia time. According to the previous single center study, mesenchymal stem
      cell (MSC) had an effect to prevent rejection and DGF after renal transplantation, but there
      was no perspective multicenter controlled study to confirm it. This perspective multicenter
      controlled study will focus on clarifying the key role of MSC applied via renal arterial or
      peripheral vein injection, to reduce the rejection and DGF after renal transplantation. The
      investigators have established GMP workshop and solid research foundation of transplant
      rejection. This study will provide a new reasonable way for immune induction of renal
      transplantation by DCD.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of participants enrolled into the MSC group and control group</measure>
    <time_frame>up to one year</time_frame>
    <description>80-100 cases will be enrolled to the group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incident rates of BPAR and DGF after renal transplantation with MSC prevention before operation</measure>
    <time_frame>up to one year</time_frame>
    <description>Cases enrolled into the group will be monitored renal function,renal biopsy and other opportunistic infection.The incident rates of DGF and BPAR will be calculated and compare with the control group.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Disorder Related to Renal Transplantation</condition>
  <condition>Renal Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>iv of BMSC to prevent rejection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC iv(2*10^6cell/kg, 48h before op)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>routine treatment protocol to prevent rejection</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ia and iv of MSC to prevent rejection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC (iv 2*10^6cell/kg + ia 5*10^6cell, 48h before op)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>routine treatment to prevent rejection</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine CMR treatment plus MSC to prevent CMR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)+MSC( iv 2*10^6cell/kg at d1,d7)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine CMR treatment to prevent CMR</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine AMR treatment plus MSC to prevent AMR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)+MSC( iv 2*10^6cell/kg at d1,d7)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine AMR treatment to prevent AMR</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mesenchymal stem cell</intervention_name>
    <arm_group_label>iv of BMSC to prevent rejection</arm_group_label>
    <arm_group_label>ia and iv of MSC to prevent rejection</arm_group_label>
    <arm_group_label>Routine CMR treatment plus MSC to prevent CMR</arm_group_label>
    <arm_group_label>Routine AMR treatment plus MSC to prevent AMR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Study on prevention of MSC to rejection after transplantation

               -  Age between 18-60 years

               -  having the indication of renal transplantation

               -  having no absolute contraindication

               -  renal transplantation by donation after citizen death

               -  the first time to receive renal transplantation

               -  signed informed consent

          2. Study on treatment of MSC to rejection after transplantation

               -  renal transplantation by donation after citizen death

               -  BPAR

               -  having no contraindication of renal biopsy

               -  signed informed consent

        Exclusion Criteria:

          -  loss to follow-up

          -  serious adverse events
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiquan Sun, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Third Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2015</study_first_posted>
  <last_update_submitted>July 2, 2015</last_update_submitted>
  <last_update_submitted_qc>July 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Qipeng Sun</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Renal transplantation</keyword>
  <keyword>mesenchymal stem cell</keyword>
  <keyword>Transplantation Rejection</keyword>
  <keyword>donation after cardiac death</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

